BioPharmSignal logoBioPharmSignal

Biotech News

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

KalVista Pharmaceuticals, Inc. (KALV)KalVista Pharmaceuticals, Inc.Clinical readout

Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 30, 2026-- KalVista Pharmaceuticals, Inc.

Related news

KALVKalVista Pharmaceuticals, Inc.2026-03-20 11:00 EST

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference

KALVKalVista Pharmaceuticals, Inc.2026-05-28 11:00 EST

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

View all latest news

KalVista Pharmaceuticals, Inc.

Hereditary Angioedema Company KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks. EKTERLY EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is...

Recent company news

KALVKalVista Pharmaceuticals, Inc.2026-06-11 12:41 EST

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

KALVKalVista Pharmaceuticals, Inc.2026-05-28 11:00 EST

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KALVKalVista Pharmaceuticals, Inc.2026-04-29 11:00 EST

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

KALVKalVista Pharmaceuticals, Inc.2026-04-08 11:00 EST

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KALVKalVista Pharmaceuticals, Inc.2026-04-02 20:01 EST

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
26.95 USD
Market cap
1.43B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States